c.moreau98/100
Consistency: 8 lots, purity band under 0.7 points wide. Janoshik report held on file, figures match published.
HYB — Shenzhen Hybio Pharmaceutical Co., Ltd.
Shenzhen, CN · established 2003. The index holds 241 assay reports across 40 batches and 25 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where HYB sells
Shenzhen Hybio Pharmaceutical Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit HYB at hybiopharmaceutical.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Shenzhen Hybio Pharmaceutical Co., Ltd.
- Short code in this index
- HYB
- Also known as
- HYB · Hybio Pharmaceutical · Shenzhen Hybio Pharmaceutical · 深圳翰宇药业股份有限公司
- City
- Shenzhen
- Region
- Guangdong
- Country
- CN
- Established
- 2003
- First record in index
- 29 Apr 2024
- Most recent record
- 07 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
14.9%
n=241
Retail, shipped to the buyer
79.7%
n=241
Direct to the laboratory
0.8%
n=241
Median courier leg, direct despatch
suppressed
n=2
n<3 — see individual records
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 36 | 14.9% |
| Retail purchase, shipped to the buyer | 155 | 64.3% |
| Retail purchase via a third-party forwarder | 37 | 15.4% |
| Supplier despatch direct to the laboratory | 2 | 0.8% |
| Laboratory retained-sample archive | 11 | 4.6% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 241 HYB records the index holds, 36 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 17 of the 25 compounds HYB is represented by here — Semaglutide, Tirzepatide, L-Glutathione (reduced), Retatrutide, Exenatide, GHRP-2 and 11 further compounds. Those are the HYB lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents HYB stock held in Netherlands, with a transit of 5 working days against a quoted 6. Netherlands is the only regional stock location named anywhere in HYB's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is HYB's own reviewers: 6 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.37%
n=241
Interquartile range
0.89pp
n=241
10th percentile
98.40%
n=241
Pass rate vs index spec
100.0%
n=241
Median recovery vs claim
98.0%
n=146
Median water
4.53%
n=241
Median |mass error|
2.8ppm
n=201
Records carrying a flag
17.8%
n=241
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.68pp
n=30
Index median spread
0.67pp
n=28
Lots tested 3+ times
30
n=40
Across the 30 HYB lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.68 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.06pp
n=40
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
65%
n=40
Divergences beyond 1 pp
3%
n=40
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
99.38%
n=228
Supplier-supplied median
suppressed
n=2
n<3 — see individual records
Supplier-supplied share of records
0.8%
n=241
Too few records in one or both provenance classes (buyer-sourced n=228, supplier-supplied n=2) to compute a provenance gap for HYB. The index-wide effect is +0.31 pp and applies until measured otherwise.
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of HYB batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
89/100
n=40
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 73% | 25 points | |
| Peptide content stated | 48% | 20 points | |
| Endotoxin stated | 38% | 15 points | |
| Named impurities rather than a total | 65% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 29 | 98.70 | 98.55 | +0.15 | 97.0 | 100 |
| Semaglutide | Incretin | 24 | 98.92 | 98.89 | +0.03 | 97.0 | 100 |
| Retatrutide | Incretin | 21 | 98.35 | 98.37 | -0.02 | 96.5 | 100 |
| BPC-157 | Tissue-repair | 16 | 99.39 | 99.16 | +0.23 | 98.0 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 16 | 99.26 | 99.09 | +0.17 | 98.0 | 100 |
| Triptorelin | Hypothalamic | 12 | 99.46 | 99.41 | +0.05 | 98.5 | 100 |
| IGF-1 LR3 | Growth-hormone | 12 | 98.90 | 98.28 | +0.62 | 95.0 | 100 |
| L-Glutathione (reduced) | Short | 12 | 99.39 | 99.33 | +0.06 | 98.5 | 100 |
| GHRP-2 | Growth-hormone | 12 | 99.86 | 99.28 | +0.58 | 99.0 | 100 |
| MOTS-c | Metabolic | 11 | 99.54 | 99.13 | +0.41 | 98.0 | 100 |
| Hexarelin | Growth-hormone | 11 | 99.93 | 99.59 | +0.34 | 99.0 | 100 |
| MGF | Growth-hormone | 9 | 99.74 | 99.29 | +0.45 | 97.5 | 100 |
| Exenatide | Incretin | 9 | 98.74 | 98.98 | -0.24 | 98.0 | 100 |
| ARA-290 | Tissue-repair | 8 | 99.34 | 99.42 | -0.08 | 98.0 | 100 |
| SS-31 (Elamipretide) | Metabolic | 6 n=6 | 99.68 | 99.53 | +0.15 | 98.5 | 100 |
| Enclomiphene citrate | Non-peptide | 6 n=6 | 99.66 | 99.44 | +0.21 | 98.5 | 100 |
| Dihexa | Neuroactive | 6 n=6 | 99.64 | 99.63 | +0.01 | 98.5 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 5 n=5 | 99.87 | 99.49 | +0.38 | 98.5 | 100 |
| Epitalon | Short | 4 n=4 | 99.80 | 99.56 | +0.24 | 99.0 | 100 |
| Melanotan II | Melanocortin-receptor | 3 n=3 | 99.46 | 99.42 | +0.04 | 98.5 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 3 n=3 | 99.27 | 99.38 | -0.11 | 98.5 | 100 |
| KPV | Tissue-repair | 2 n=2 | n<3 | 99.64 | — | 99.0 | 100 |
| GHRP-6 | Growth-hormone | 2 n=2 | n<3 | 99.54 | — | 99.0 | 100 |
| CJC-1295 with DAC | Growth-hormone | 1 n=1 | n<3 | 98.95 | — | 97.5 | 100 |
| Selank | Neuroactive | 1 n=1 | n<3 | 99.59 | — | 99.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 0 | 0 | n<3 | — | 0 |
| 2024-Q2 | 2 | 7 | 99.24 | 98.45–99.93 | 0 |
| 2024-Q3 | 5 | 41 | 99.16 | 98.08–99.93 | 2 |
| 2024-Q4 | 3 | 26 | 99.23 | 98.51–99.93 | 12 |
| 2025-Q1 | 4 | 24 | 99.69 | 97.96–99.93 | 8 |
| 2025-Q2 | 3 | 23 | 99.57 | 99.18–99.93 | 3 |
| 2025-Q3 | 3 | 26 | 99.26 | 98.01–99.93 | 0 |
| 2025-Q4 | 6 | 24 | 99.72 | 98.90–99.93 | 3 |
| 2026-Q1 | 7 | 34 | 99.38 | 97.85–99.93 | 10 |
| 2026-Q2 | 5 | 24 | 99.03 | 98.33–99.93 | 3 |
| 2026-Q3 | 2 | 12 | 99.53 | 98.29–99.93 | 2 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 109 | 99.33 | +0.00 | 99.33 |
| PeptideMeter | 32 | 99.34 | -0.05 | 99.39 |
| Medutest | 44 | 99.44 | +0.08 | 99.36 |
| VendorInvestigate | 19 | 99.09 | -0.11 | 99.20 |
| Nordanalyt | 22 | 99.30 | +0.02 | 99.28 |
| Kestrel | 15 | 99.82 | +0.24 | 99.58 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
96.0/ 100812 ratings across the index network
ha.mwangi97/100
Certificate carries counter-ion identity and content. Complete against the index minimum data set at first issue. Research use. Not approved for human administration.
n.beaulieu99/100
Lot HYB-26-518 submitted to PeptideMeter. Declared 99.0%, reported 99.1%. Delta inside method repeatability. PeptideMeter report held on file, figures match published.
ay.boateng96/100
Transit 5 days from stock held in Netherlands against a quoted 6. Customs documentation correct at first presentation.
ro.okwuosa98/100
Release signed and dated, named individual. Per-milligram figure calculated against the certificate rather than against nominal fill, and it reconciled.
jo.vasquez100/100
Custom synthesis delivered 3 days inside the quoted schedule at the specified purity. Figures as reported by the named service. Not reproduced by the index.
fr.chukwu95/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Submitted to the index in full.
ju.coelho97/100
Blind submission of semaglutide 5 mg to Medutest, origin withheld. 99.2% against 99.0% declared. Figures as reported by the named service. Not reproduced by the index.
y.erdogan96/100
Fill uniformity: 12 units weighed against declared fill, all within 2%. No further comment.
j.hartmann99/100
Cross-check: Janoshik and VendorInvestigate, same lot, agreement to 0.1 points. Both agree with the declared figure. Record covers the lots named. Not generalised.
am.ekstrom94/100
Batch record supplied in full on request, attached rather than summarised. Independent verification of individual lots still required.
t.nakamura98/100
Cold chain intact. Phase-change pack solid at arrival, day 4. Evidence base adequate for a rating on this criterion.
ha.tulloch100/100
Quote correct at first issue and held to invoice. Published stock status matched availability. Same-day dispatch.
n.sjoberg96/100
Bulk API line quoted per gram of declared peptide content rather than per unit, which is the only comparison that survives a content figure. Contributor declares no interest beyond the transaction.
ay.ivaturi97/100
Documentation complete at first issue. No supplementary request raised. VendorInvestigate report held on file, figures match published.
ro.laurent95/100
Labelling printed, lot and date legible on every unit examined. Identifier matches across vial, certificate and commercial documentation.
jo.yildiz99/100
Repeat determination at 11 months: 98.9%. Original: 99.0%. No drift detected in this sample. n=1, declared as n=1.
fr.sandvik98/100
Supplementary certificate for a lot released 14 months earlier retrieved from supplier records on request. Peptide content 98.8%.
ju.ramos93/100
Line quoted that two comparable suppliers declined to quote. Material returned within specification. Not medical advice.
y.okonkwo97/100
Reconstitution of tesamorelin 10 mg: clear on contact, no haze, no particulate. Not medical advice.
e.krastev96/100
Two lots ordered deliberately for comparison. Reported purities 0.2 points apart. Desiccant enclosed within the secondary container.
am.lundgren100/100
Dispatch on the quoted day through a public holiday week, with the despatch note timed. Material returned 99.1%.
t.vermeulen94/100
Declared figure not adjusted upward between certificate and commercial documentation. Gradient and column chemistry stated.
ha.diallo98/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Declared and independent figures differ by less than repeatability.
n.petrescu92/100
4 orders, 21 months. No substitution, no reformulation, no post-payment unavailability. Catalogue availability matched the published catalogue.
ay.roos97/100
Packing: a rigid outer with no rattle anywhere in it. Storage condition for the stability statement stated on the certificate.
Block 12
Most recent records
Block 13
Contributor annotations on HYB records 445
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on HYB material are below, each linked to the record it sits on.
Epimerisation during activation produces a diastereomer that is mass-identical and only chromatographically separable. At this gradient length the separation exists, and 99.93 % is net of it.
A high figure on one vial is a statement about one vial. The within-lot spread on the batch rollup is what tells you whether the bulk was well mixed, and it is the rarer and more useful number.
A single excursion of this size against a clean run of prior results on the same instrument is a calibration event with a date on it. The laboratory's own sequence log would place it; the index does not hold one.
The dataset stores signed ppm error, so the direction survives into the CSV. Anyone aggregating absolute values should take the modulus explicitly rather than relying on the field.
Ion suppression from a co-eluting counter-ion at 3.54 % acetate can shift an apparent mass in a time-of-flight measurement. Desalting the injection before the mass determination removes the possibility.
At this mass the monoisotopic peak may not be the most intense peak in the cluster. Picking the apex instead of the monoisotopic peak produces a systematic positive error of roughly the size flagged here.
Independently purchased, at the submitter's own cost, forwarded without the supplier's involvement. That is the definition and this record meets it.
At 99.54 % the deletion-sequence family is at or below the reporting threshold. On a sequence with a hindered coupling that is a statement about coupling efficiency, and a good one.
Every annotation the index holds on HYB material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what HYB itself publishes, open hybiopharmaceutical.com → alongside.
Block 14
Where to buy HYB
Shenzhen Hybio Pharmaceutical Co., Ltd. sells direct from hybiopharmaceutical.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the HYB store at hybiopharmaceutical.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.